Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women

Annals of Internal Medicine

Volumn 155, Issue 11, 2011, Pages 751-761

  Nayak, Smita ^a   Roberts, Mark S ^a   Greenspan, Susan L ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; HIP FRACTURE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION TOOL; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 82855169228     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-11-201112060-00007     Document Type: Article

References (64)

1. National Osteoporosis Foundation. About Osteoporosis: Fast Facts. Washington, DC: National Osteoporosis Foundation; 2005.
2. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-41. [PMID: 12230356]
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75. [PMID: 17144789]
4. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
5. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166:1209-17. [PMID: 16772249]
6. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605-15. [PMID: 18778176]
7. Schousboe JT. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep. 2007;9:50-6. [PMID: 17437668]
8. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137: 526-8. [PMID: 12230355]
9. Centers for Medicare & Medicaid Services. National Physician Fee Schedule. Accessed at www.cms.hhs.gov/PFSlookup/ on 2 March 2011.
10. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc. 2005;53:1697-704. [PMID: 16181168]
11. Kraemer DF, Nelson HD, Bauer DC, Helfand M. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women. Osteoporos Int. 2006;17:68-76. [PMID: 15889313]
12. Lacroix AZ, Buist DS, Brenneman SK, Abbott TA 3rd. Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. Med Care. 2005;43:293-302. [PMID: 15725986]
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8. [PMID: 8849754]
14. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett- Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. [PMID: 9875874]
15. Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen IE, et al. Metaanalysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144:832-41. [PMID: 16754925]
16. Brenneman SK, Lacroix AZ, Buist DS, Chen YT, Abbott TA 3rd. Evaluation of decision rules to identify postmenopausal women for intervention related to osteoporosis. Dis Manag. 2003;6:159-68. [PMID: 14570384]
17. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-89. [PMID: 9850356]
18. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK. Costeffectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006;26:194-206. [PMID: 16525173]
19. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165: 2414-9. [PMID: 16287772]
20. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-38. [PMID: 17190893]
21. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25:976-82. [PMID: 20200926]
22. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-65. [PMID: 20173017]
23. Fraser LA, Vogt KN, Adachi JD, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag. 2011;7:157-66. [PMID: 21691586]
24. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010;16: 1016-9. [PMID: 21216723]
25. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-73. [PMID: 7862179]
26. Melton LJ 3rd, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113-9. [PMID: 8481586]
27. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997;277:1159-64. [PMID: 9087473]
28. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-43. [PMID: 7477143]
29. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al; Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24. [PMID: 11095442]
30. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. [PMID: 8950879]
31. Tosteson AN, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int. 2001;12:849-57. [PMID: 11716188]
32. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56:1-39. [PMID: 18274319]
33. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38-42. [PMID: 14593451]
34. Office of Technology Assessment. Hip fracture outcomes in people age 50 and over - background paper. Washington, DC: US Congress, Office of Technology Assessment; July 1994. OTA-BP-H-120.
35. Corliss GR, Lucas R, Newton M, Tillman K. Long-term care experience committee intercompany study 1984-2001. Society of Actuaries. November 2004;4th report:1-70.
36. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc. 2003;51:364-70. [PMID: 12588580]
37. Red Book. Montvale, NJ: Thomson Reuters; 2010.
38. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-30. [PMID: 12035765]
39. GE Financial Nursing Home Cost of Care Survey. Richmond, VA: GE Financial Assurance Holdings; 2003.
40. Walmart Pharmacy Medication Finder. Accessed at http://medicationfinder.walmart.com/mapd/MedicationFinder.jsp on 16 December 2010.
41. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391-400. [PMID: 16855127]
42. Brazier JE, Green C, Kanis JA; Committee Of Scientific Advisors International Osteoporosis Foundation. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int. 2002;13:768-76. [PMID: 12378365]
43. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15:1384-92. [PMID: 10893688]
44. Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles' fracture patients. Osteoporos Int. 1999;9:196-9. [PMID: 10450406]
45. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.[PMID: 8483408]
46. Brazier JE, Kohler B, Walters S. A prospective study of the health related quality of life impact of hip fracture. Sheffield, United Kingdom: ScHARR, University of Sheffield, Sheffield; 2000.
47. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15: 20-6. [PMID: 14593450]
48. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1-134. [PMID: 19788058]
49. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-8. [PMID: 2818106]
50. Barrett JA, Baron JA, Karagas MR, Beach ML. Fracture risk in the U.S. Medicare population. J Clin Epidemiol. 1999;52:243-9. [PMID: 10210242]
51. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
52. Geusens P, Hochberg MC, van der Voort DJ, Pols H, van der Klift M, Siris E, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc. 2002;77:629-37. [PMID: 12108600]
53. Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, Brown JP; Canadian Multicentre Osteoporosis Study. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 2001;286:57-63. [PMID: 11434827]
54. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al; Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947-54. [PMID: 14606506]
55. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:734-41. [PMID: 15867405]
56. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int. 1998;8 Suppl 4:S7-80. [PMID: 10197173]
57. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9. [PMID: 15616758]
58. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40. [PMID: 11172164]
59. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13:340-67. [PMID: 16735931]
60. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004; 103:203-16. [PMID: 14704265]
61. Lu Y, Genant HK, Shepherd J, Zhao S, Mathur A, Fuerst TP, et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res. 2001;16:901-10. [PMID: 11341335]
62. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-61. [PMID: 16007889]
63. U.S. Consumer Price Index for Medical Care for All Urban Consumers. U.S. Department of Labor, Bureau of Labor Statistics.
64. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001;12:1042-9. [PMID: 11846331]